Shots:
- Accord BioPharma, a division of Intas Pharmaceuticals, has launched Imuldosa (ustekinumab-srlf), a biosimilar to Stelara
- The launch includes a $0 co-pay program for eligible pts with plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis
- Through an exclusive deal with Bio-Thera Solutions, Accord plans to introduce BAT2506, a biosimilar to Simponi, to the U.S. market and has submitted multiple biosimilar applications to the FDA
Ref: PRNewsWire | Image: Accord BioPharma | Press Release
Related News:- Accord BioPharma’s Hercessi 420mg (Biosimilar, Herceptin) Receives the US FDA’s Approval to Treat Various HER2-Overexpressing Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
